Sun Pharma Advanced Research Company Ltd
Sun Pharma Advanced Research Company Ltd (SPARC) last reported results for the quarter ended Jun 2026, with sales of ₹40 crore and net profit of ₹-21 crore. The stock last traded at ₹195, a market capitalisation of ₹6,340 crore, on a P/E of 3.95. Over the past 52 weeks the stock has ranged between ₹108 and ₹289. Figures are as of 6 Oct 2026 and are not real time.
Sun Pharma Advanced Research Company Ltd share price and key metrics
- Current price
- ₹195
- Market cap
- ₹6,340 cr
- Stock P/E
- 3.95
- Book value
- ₹41.3
- ROE
- 279%
- ROCE
- 164%
- Dividend yield
- 0.00%
- 52w high / low
- 289/108
Metrics as of 6 Oct 2026. Not real time.
Track Sun Pharma Advanced Research Company Ltd
Cruxal reads every Sun Pharma Advanced Research Company Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Sun Pharma Advanced Research Company Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 99%
- TTM
- 2856%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 108%
- TTM
- 635%
- 10 Years
- -5%
- 5 Years
- -8%
- 3 Years
- -6%
- 1 Year
- 45%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- Last Year
- 279%
Sun Pharma Advanced Research Company Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹40 cr, up 300.0% from ₹10 cr a year earlier. Net profit was ₹-21 cr, up 59.6% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 13 | 15 | 27 | 10 | 8 | 8 | 1,853 | 40 |
| Expenses | 116 | 89 | 80 | 62 | 74 | 65 | 80 | 74 |
| Operating profit | -103 | -74 | -53 | -52 | -66 | -57 | 1,773 | -34 |
| OPM % | -800% | -494% | -196% | -540% | -836% | -670% | 96% | -85% |
| Other income | 0 | 0 | 0 | 9 | 0 | -12 | 2 | 24 |
| Interest | 1 | 3 | 5 | 6 | 8 | 9 | 12 | 8 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 |
| Profit before tax | -107 | -79 | -61 | -52 | -76 | -80 | 1,761 | -21 |
| Tax % | 0% | 0% | -1% | 0% | 0% | 0% | -0% | 1% |
| Net profit | -107 | -80 | -60 | -52 | -76 | -80 | 1,761 | -21 |
| EPS (₹) | -3.31 | -2.45 | -1.84 | -1.60 | -2.34 | -2.48 | 54.27 | -0.64 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Sun Pharma Advanced Research Company Ltd annual results
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|
| Sales | 239 | 76 | 72 | 1,879 | 1,909 |
| Operating profit | -214 | -402 | -323 | 1,599 | 1,617 |
| OPM % | -90% | -532% | -450% | 85% | 85% |
| Net profit | -223 | -387 | -343 | 1,553 | 1,584 |
| EPS (₹) | -6.86 | -11.93 | -10.55 | 47.86 | 48.81 |
TTM is the trailing twelve months to the most recent quarter.
Sun Pharma Advanced Research Company Ltd balance sheet
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity capital | 32 | 32 | 32 | 32 |
| Reserves | 480 | 93 | -249 | 1,306 |
| Borrowings | 16 | 61 | 269 | 559 |
| Other liabilities | 302 | 328 | 284 | 273 |
| Total liabilities | 830 | 515 | 336 | 2,171 |
| Fixed assets | 106 | 108 | 99 | 85 |
| CWIP | 27 | 44 | 54 | 72 |
| Investments | 291 | 2 | 0 | 0 |
| Other assets | 406 | 362 | 183 | 2,014 |
| Total assets | 830 | 515 | 336 | 2,171 |
As reported by the company. Total assets equal total liabilities by construction.
Sun Pharma Advanced Research Company Ltd cash flow
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Cash from operations | -69 | -429 | -360 | -239 |
| Cash from investing | -548 | 392 | 158 | -23 |
| Cash from financing | 617 | 42 | 199 | 261 |
| Net cash flow | -1 | 5 | -3 | -1 |
| Free cash flow | -84 | -455 | -370 | -262 |
| CFO / operating profit | 35% | 106% | 114% | -17% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Sun Pharma Advanced Research Company Ltd operating ratios
| Per year | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| ROCE % | — | -108% | -279% | 164% |
| Debtor days | 50 | 75 | 82 | 2 |
| Cash conversion cycle | 50 | 75 | 82 | 2 |
| Working capital days | -193 | -738 | -1,780 | 215 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Sun Pharma Advanced Research Company Ltd shareholding pattern
Promoters held 65.68% at Jun 2026, broadly unchanged since Jun 2025. FIIs 3.90% and DIIs 0.09%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 65.68% | 65.68% | 65.68% | 65.67% | 65.67% | 65.67% | 65.67% | 65.68% |
| FIIs | 2.15% | 2.23% | 1.45% | 1.47% | 1.76% | 2.04% | 2.04% | 3.90% |
| DIIs | 0.21% | 0.64% | 1.13% | 0.97% | 1.05% | 0.78% | 0.88% | 0.09% |
| Public | 31.96% | 31.47% | 31.76% | 31.88% | 31.52% | 31.51% | 31.41% | 30.34% |
| No. of shareholders | 1,28,205 | 1,31,034 | 1,42,864 | 1,40,724 | 1,36,997 | 1,44,810 | 1,40,625 | 1,41,957 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Sun Pharma Advanced Research Company Ltd corporate filings
- Confirmation Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018Company Updatelow impact
- Sun Pharma Advanced Research Company Ltd updates on litigation under SEBI regulation 30, no financial impact reportedCompany Updatelow impact
Cruxal's analysis: The company has issued an update regarding ongoing litigation, as per SEBI regulation 30…
Read the full analysis - Intimation regarding Closure of Trading WindowInsider Trading / SASTlow impact
- Sun Pharma Advanced Research Company Ltd files application for reclassification of promoter/promoter groupCompany Updatelow impact
Cruxal's analysis: Sun Pharma Advanced Research Company Ltd has submitted an application to the stock…
Read the full analysis - Sun Pharma Advanced Research Company Ltd publishes mandatory newspaper advertisement for financial resultsCompany Updatelow impact
Cruxal's analysis: The company has fulfilled its regulatory obligation under Regulation 30 of the SEBI…
Read the full analysis - Sun Pharma Advanced Research Company (SPARC) Reports Debt-Free Status Following US$195 Million PRV Monetization and Strategic RestructuringAGM/EGMhigh impact
Cruxal's analysis: Sun Pharma Advanced Research Company (SPARC) has successfully monetized a Paediatric Rare…
Read the full analysis - Sun Pharma Advanced Research Company Ltd releases Monitoring Agency Report for quarter ended June 30, 2026Company Updatelow impact
Cruxal's analysis: The company has filed its Monitoring Agency Report for the quarter ended June 30, 2026…
Read the full analysis - Sun Pharma Advanced Research Company (SPARC) Reports Q1 FY27 Results and Promoter Group ReclassificationBoard Meetingmedium impact
Cruxal's analysis: Sun Pharma Advanced Research Company Limited reported a net loss of 20.78 crore for the…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.